• Research Reagents >

High Throughput Isolation Of T Cells For The Treatment Of Metastatic Cancer

Background:
The National Cancer Institute's Surgery Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize high throughput T cell isolation technology.

Technology:
The adoptive transfer of autologous antigen reactive lymphocytes has been shown to mediate significant tumor regression in some patients with metastatic cancer.  However, the isolation of these T lymphocytes typically requires invasive surgery, which can lead to post-operative complications and delays in initiating adoptive immunotherapy with T cells.

This technology is directed to the use of a novel high throughput technique to isolate highly enriched tumor reactive lymphocytes in a non-invasive manner from the peripheral blood of cancer patients.  The isolated T lymphocytes can be used in adoptive immunotherapy for the treatment of metastatic cancer.  The technique is rapid, easy to use, and utilizes a highly sensitive PCR based screening assay.  The method can detect the presence of extremely rare T cells in a bulk population of peripheral blood cells.

Further R&D Needed:

• Robotic Automation to enhance throughput of T cell isolation and cloning
• Isolation of virus specific T cells for potential anti-viral therapy

• U.S. Patent Application No. 61/027,623 filed 11 Feb 2008

• Rapid, easy to use, non-surgical technique utilizes a highly sensitive PCR based screening assay for isolating tumor reactive T cells
• Method can detect the presence of extremely rare T cells in a bulk population of peripheral blood cells.